Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vismodegib in Recurrent or Refractory Medulloblastoma
NCT01239316Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2010
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vismodegib in medulloblastoma, sponsored by National Cancer Institute. Started Nov 2010; status: completed.
02
Drugs
vismodegib
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on NCT01239316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01239316.